Ardelyx Inc. (NASDAQ:ARDX) Stock On The Watchlist After The Recent News
Ardelyx Inc. (NASDAQ:ARDX) is in focus after announcing the publication of its long-term 52-week third phase PHREEDIM study in the American Society of Nephrology Journal, Kideny360.CEO and President Mike Raab said that the study assessed tenapanor monotherapy. It was the third of the three third phase studies conducted in the evaluation of tenapanor for serum phosphorous control in chronic kidney disease patients on dialysis. Mike said that the data from…









